Please assess the completion status of the following clinical trial:

Trial Title: Bivalirudin as a Procedural Anticoagulant in Pediatrics

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Male and non-pregnant females, with an age range of birth to 16 years of age.~* Expected to undergo a percutaneous intravascular procedure for the management of congenital heart disease.~* Written informed consent from a legal guardian/parent.~* Life expectancy of at least 15 days at study entry.~* Assent of the patient if older than 8 years, whenever possible.~Exclusion Criteria:~* History of intracerebral bleed (neonates confirmed by an ultrasound head scan prior to procedure), or cerebral arteriovenous malformation or any prior bleed with neurological deficit.~* Gastrointestinal or genitourinary bleeding within the last 2 weeks excluding normal menstrual cycles.~* Cerebrovascular accident within 6 months, or any cerebrovascular accident with a residual neurological deficit.~* Known congenital or acquired bleeding or clotting disorder.~* Patients undergoing renal dialysis.\*~* Weight \< 2.5 kg.~* Confirmed pregnancy at time of enrollment or breast feeding (females of child-bearing potential).~* Known allergy to bivalirudin or hirudin-derived drugs, or known sensitivity to any component of bivalirudin (Angiomax®).~* Any condition that in the investigator's opinion would constitute a contraindication to participation in the study, or cause inability to comply with the study requirements.~* Participation in another investigational therapeutic drug or therapeutic device trial within 30 days of starting study.~* Patients who have been receiving warfarin (Coumadin®) therapy and whose INR is \> 1.5.~* Patients who cannot be discontinued from UFH at least 30 minutes prior to study drug bolus.~* Patients who have received a dose of LMWH within 8 hours prior to study drug bolus.~* Patients previously enrolled in the study.

- Gender: ALL
- Minimum Age: None
- Maximum Age: 16 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).